{"name":"Second Life Therapeutics","slug":"second-life-therapeutics","ticker":"","exchange":"","domain":"","description":"Second Life Therapeutics is a biotechnology company focused on developing innovative treatments for patients with unmet medical needs. The company's lead candidate, SL-28, is currently in Phase 2 clinical trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"SL-28.","genericName":"SL-28.","slug":"sl-28","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"SL-28.","genericName":"SL-28.","slug":"sl-28","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixgJBVV95cUxNUUxicUhFQ0s3XzYxOElTeC1EaHZ1MVcyajlOUVNuTlNBUjRDLXhCenU2R2t0NTdwZHBucEZ0NENKTUZaLXhEQWtrU01KejhGTmIyckRpbzJ0bGI2RDJQeU1LX0s5akJWSEFnQ1dpQTIwSkF5Y0NCdk1qSy1HeERQZ0ZoOXhTd3FjekVWNllqZFZmWHlfeUdvZ2RiNXRWbkUtZUFsN2hWNWg5UkNCaVY2c1MzZVNlczFZcXltVWRDcndQR3hpSDVIdlFQQ2xpR3Fza1lmejlkS0E2dzZYODBydFN0Mm1pbjdiX250OEw3ZHNwbWV0ZWxFcjNBQzFGNExyOUc3WURsUUxVdFBEb1NCTjlZR2VyWDZaNlgtZzJLa3ZmU3FMY000alQwcEJja1dWTm5USXBuSmhCbmJuTXdYM05jVFc5UQ?oc=5","date":"2026-02-24","type":"pipeline","source":"GlobeNewswire","summary":"Jeito Capital Makes Significant Investment in the Second - GlobeNewswire","headline":"Jeito Capital Makes Significant Investment in the Second","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxNUmNoV0gzbm1QazN5UjctblJkN2U1dGpLYzJ0dTUxRGNvcHZsOW1zeDBaQUdENWxObWxhMm1vejRKMVFfQ0QtZnZBRXJJRW9heFdvcW9yWC11LXlIOHNRZnRJTUZKbVdqSE9kenh3U2Vic1hEV1lxNWhuYUZXa0ZFSmJZYS11RU1lSV9XWjU5WExQZmJYa1JoZ1E5elBETWNmVE1GWg?oc=5","date":"2025-12-16","type":"deal","source":"PwC","summary":"Pharmaceutical and life sciences: US Deals 2026 outlook: M&A Trends - PwC","headline":"Pharmaceutical and life sciences: US Deals 2026 outlook: M&A Trends","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxNT1M4NWxPLTJISlRTTXBETnR4aVAzY1h4TlZZSlVXOEtBMUJDajlucm15SjBMbWpNMFJqaUUtMnBxcDc4RWpnS0l0S2RXQ0llQmc1aGp0QWtvaHRxcGZQdExGSWIxczF5cnQ2Ujd1d0VsTVJNVEJXZXBvaW1Hd0VYeERXU25NSVF0RC03MDNHRWpBbnhZMUtncE4tMFdIWGNOdUxMd2lLcjdnZlAwb2dYTFQ5cUN0aEk?oc=5","date":"2025-12-08","type":"pipeline","source":"pharmaphorum","summary":"Radiopharmaceutical innovation: Giving cancer drugs second chances and creating new therapeutic possibilities - pharmaphorum","headline":"Radiopharmaceutical innovation: Giving cancer drugs second chances and creating new therapeutic possibilities","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxONjZrcHd5enYyLTVnYy02NTEyS2ZGeWY3ZFBxeEFSd0t0dFV1ZzBhVU4zanpOM3dBb1Fhd2djNngtREZBeTFURzJ1Z1hzR05Zc2tXZ3dKQUhseURGRmQ2SjViM0hCWGRMbHNtMVh0WkhKbXlXdkxkWS1OLWRlc2FvVnEwd2tCTDJCT2FCVVk5OEFpSXBMeGFsVDlWbWtMelRCVjV1WkZyUHZUSUFyUUNYaGxpaVU?oc=5","date":"2025-11-04","type":"pipeline","source":"BioSpace","summary":"Opinion: Pharma Is Sitting on Hidden Cures. Find Your ‘Freda’ To Unlock Them - BioSpace","headline":"Opinion: Pharma Is Sitting on Hidden Cures. Find Your ‘Freda’ To Unlock Them","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBEdnZOdWlxcThDanp4UElKaGN1M0E0ZkVlaWpDNUlCMWxWRDJzV3oyWmdNRTRzMWVqU3MxRWJzV3FBUGNSeU9ETkY1NGhfUEtFY05N?oc=5","date":"2025-10-16","type":"pipeline","source":"FirstWord Pharma","summary":"Friday Five: ESMO looms large, Arcus' second life for TIGIT, J&J ups its myeloma game, and more… - FirstWord Pharma","headline":"Friday Five: ESMO looms large, Arcus' second life for TIGIT, J&J ups its myeloma game, and more…","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7wFBVV95cUxOOXJsX2hWMEpiLWZ6MjBNdDk5NURsOHBYaEM2WDJIYThoc3JlUU5DNm5yLWZJWHVHSkx2NE9EYzdNX3RKS2xzeWVneVBaZ3d0ZGN1RGN0VjRXaFh6RXN6M1lweHBCME5QLUdzQmYyZW5ta3llM2tETDRjM1g3MVhLMWt3QmxVQnM3MlN6WHRVQW9HTm0wRTg4VEk4MXdyMDZoTHVSRlFzdWxlbkhQdTgyYjVuXzdiYVJOSmIxRVdObDRYMDhHNEg5VjhJaHQ3cW56Q1Y3YXRqYWJwbHFUYVU0ZU9yc1BoR2VxTXdad0k4bw?oc=5","date":"2025-10-15","type":"pipeline","source":"TAPinto","summary":"Rising Pharmaceuticals Opens New 165K Sq. Ft. Plant in East Windsor - TAPinto","headline":"Rising Pharmaceuticals Opens New 165K Sq. Ft. Plant in East Windsor","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNZ0RQVmh2Z3FJeDZIM2wyOTVyQ1phTTR2Z1kxMG16R2VZejVzbzl3TnFCWVVXTUR6Tm9wanJnWDZ2MEhCT2d0UDhncjVnRnFlUVcxZWwxbjJhTlBEUjVDV1lmVUctaFp5MVV5VHFpZ3JyeGg0WmRoRVA5clNOcGwzS19UQlpSek01UGEzR1NYQWxhY05oTjRjX0RadnQ3bHlOc2c?oc=5","date":"2025-10-02","type":"trial","source":"Clinical Trials Arena","summary":"Using AI to forge the future of rare disease clinical trials - Clinical Trials Arena","headline":"Using AI to forge the future of rare disease clinical trials","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxPUkgwTU44VmtGSFM2SHJCU3Y2WGlnQnAtV3pFS1lWaVFJWDNlMzZKNVJHSWxydUw5Rk8wX2xyYUhWeDAteFUzSW1oTmhHQjV1aTRsZ3JKM0FOYWNEbU1zc216RjlpOHhGblBFUXQtRTdkb3ZkVE9Cd2l4M0E2bkR1SmFocVJNT1ZFOHpsN1dvSjBKYU14TUljRQ?oc=5","date":"2025-09-29","type":"pipeline","source":"Pharmaceutical Technology","summary":"The dangerous second life of medical waste - Pharmaceutical Technology","headline":"The dangerous second life of medical waste","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxQNGFGN011SlhVS2RmU3RqWVNackE2VnRLZUlHLTRQYmZ3aGJTazhuaTNIQUdibTcxMzJURGJsTlhCX0JaZUJxOV81OUMzd1NvTUw4VDlVdExUNlZSN0c4cGk4UzRyNmtKUGd0OUNaOTVpT1IxUWxMemNqMjI4QVR0TF9xS2xPeFZkOF81ZTBMTnlTS19aMUNOSDlIclNGUVpDU25Bd0VWUHgwOWQtRjlHX3ZEbnVqWUF5?oc=5","date":"2025-09-11","type":"pipeline","source":"The Association of the British Pharmaceutical Industry | ABPI","summary":"UK tumbles down global rankings for pharma investment and research - The Association of the British Pharmaceutical Industry | ABPI","headline":"UK tumbles down global rankings for pharma investment and research - The Association of the British Pharmaceutical Indus","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxNT0RDdEdiUC1wR213VFBwQXotR2w5LXE3TWxyeUF5TnhiM09sZ0VkOGlkMElqNDZiRkY4cjJ4TXY3cEZ2ZGthMDd6b0l1dE1lMjkwekpzYmVnYlVTaG44VWw4enZBTTFhbGdqY1FVU1VfWXF6Y0ZKOGJoOF9GVWw1SWFtVQ?oc=5","date":"2025-05-27","type":"pipeline","source":"Labiotech.eu","summary":"9 biotechs making waves in interleukin therapeutics in 2025 - Labiotech.eu","headline":"9 biotechs making waves in interleukin therapeutics in 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQVnJab2xMSlRpcVQ0a1hZVS1NcTd4V0NYVVFqZ2xWbUhHdndqX3BTUmVpcHVsdGRXT3NPcWgwNVJtaGdYNjNab0VqcGdxTGNST3k0ZnRLaEpqRldUWWI2OVE2c1lVTG9FSGc5LXdIMU4wVWd2b2dGX1RabFNIS2s2VzBUMTVTOHVUSmdyS1ZsLTdkR29rU2RvTkR3?oc=5","date":"2024-08-22","type":"pipeline","source":"statnews.com","summary":"Digital therapeutics pioneer Pear’s treatments get a second life, a year after bankruptcy - statnews.com","headline":"Digital therapeutics pioneer Pear’s treatments get a second life, a year after bankruptcy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxOX0kzR21Qd3J0dDM4aEgwNHN1eTVFLVNnWDlJYi0zbVprQkdHTlV2YlJSQlB1QWV5WTNjX2xKSjRVUWpxa3l0NlZiTjE0TVdfcEczYi1GWlVKanhUU3VQbl9LUFBIRktCRVczXzltUzB5YkM2Q3pGWW82UE1GZUk2Y3EwMTg5V0lMbEYwbFoyYnlIcnVRX0g1cHZxNkM4czdJY1dyYnlKVWtqUmhCYzducUJWRUg5NjJQc2Z3NQ?oc=5","date":"2024-02-22","type":"pipeline","source":"Business Wire","summary":"ORI Capital Raises $260 Million for Second Life Sciences Fund - Business Wire","headline":"ORI Capital Raises $260 Million for Second Life Sciences Fund","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}